Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities (PDMRs), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details rather than financial performance metrics.
Material Changes and Transactions
On April 18, 2016, GSK reported the acquisition of Ordinary shares by directors and connected persons. These acquisitions occurred at a price of 1503.58 pence per share following the re-investment of the dividend paid on April 14, 2016. The specific transactions were:
- Directors/PDMRs: Sir Andrew Witty acquired 15,070 shares; Mrs V A Whyte acquired 100 shares.
- Connected Persons: Lady C Witty (connected to Sir Andrew Witty) acquired 4,705 shares; Mr I W Whyte (connected to Mrs V A Whyte) acquired 835 shares; Mrs D Connor (connected to Mr R G Connor) acquired 534 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions and contains no forward-looking statements or risk assessments.
Investor Verification Checklist
- Verify the total number of shares acquired by Sir Andrew Witty and his connected person, Lady C Witty, totaling 19,775 shares.
- Confirm the share price of 1503.58 pence per Ordinary share at the time of the dividend re-investment.
- Review the dividend payment date of April 14, 2016, to understand the timing of the re-investment.
- Check subsequent filings for any changes in the holdings of the other connected persons listed (Mr I W Whyte and Mrs D Connor).